These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 4617780)

  • 1. Biochemical and histological effects of 1,25 dihydroxycholecalciferol (1,25-DHCC) in the osteomalacia of chronic and failure.
    Eastwood JB; Phillips ME; de Wardener HE; Bordier J; Marie P; Arnaud CD; Norman AW
    J Urol Nephrol (Paris); 1974 Dec; 80(12):984-5. PubMed ID: 4617780
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of 1,25-dihydroxycholecalciferol in renal osteopathy].
    Reutter FW; Sieber R; Olah AJ; Dambacher MA
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1880-3. PubMed ID: 531567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of vitamin D metabolites on mineralization of bone tissue and phosphocalcium metabolism disorders in the course of vitamin D deficiency osteomalacia].
    Bordier P; Miravet L; Marie P; Guéris J; Rousselet F; Norman A; Rasmussen H; Ryckewaert A
    Rev Rhum Mal Osteoartic; 1978 Apr; 45(4):241-8. PubMed ID: 353964
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of long-term therapy with calcitriol in patients with moderate renal failure.
    Healy MD; Malluche HH; Goldstein DA; Singer FR; Massry SG
    Arch Intern Med; 1980 Aug; 140(8):1030-3. PubMed ID: 6893118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophy.
    Brickman AS; Sherrard DJ; Jowsey J; Singer FR; Baylink DJ; Maloney N; Massry SG; Norman AW; Coburn JW
    Arch Intern Med; 1974 Nov; 134(5):883-8. PubMed ID: 4613310
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcitriol in disorders of bone and calcium metabolism.
    Riggs BL
    Clin Ther; 1980; 3(1):33-9. PubMed ID: 6893296
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence that different vitamin D sterols have qualitatively different effects in man.
    Rasmussen H; Bordier P
    Contrib Nephrol; 1980; 18():184-91. PubMed ID: 7353375
    [No Abstract]   [Full Text] [Related]  

  • 8. Action of 1,25-dihydroxycholecalciferol in normal and uraemic man.
    Coburn JW; Brickman AS; Massry SG; Singer FR; Norman AW
    Proc Eur Dial Transplant Assoc; 1973; 10(0):210-6. PubMed ID: 4802387
    [No Abstract]   [Full Text] [Related]  

  • 9. The clinical use of synthetic 1,25-dihydroxycholecalciferol.
    Evans IM; Boulton-Jones M; Doyle FH; Joplin GF; Lockwood M; Matthews EW; MacIntyre I
    Calcif Tissue Res; 1976 Aug; 21 Suppl():236-41. PubMed ID: 782663
    [No Abstract]   [Full Text] [Related]  

  • 10. Osteomalacia due to 1alpha,25-dihydroxycholecalciferol deficiency. Association with a giant cell tumor of bone.
    Drezner MK; Feinglos MN
    J Clin Invest; 1977 Nov; 60(5):1046-53. PubMed ID: 908749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcium phosphate metabolism during therapy with 1,25-dihydroxycholecalciferol [1,25 DHCC (Ro 21/5535)] in patients with advanced kidney insufficiency].
    Schulz W; Spiegel P; Gessler U; Delling G
    Verh Dtsch Ges Inn Med; 1978; (84):1297-301. PubMed ID: 741953
    [No Abstract]   [Full Text] [Related]  

  • 12. Metabolites of vitamin D in human vitamin-D deficiency: effect of vitamin D3 or 1,25-dihydroxycholecalciferol.
    Papapoulos SE; Clemens TL; Fraher LJ; Gleed J; O'Riordan JL
    Lancet; 1980 Sep; 2(8195 pt 1):612-5. PubMed ID: 6107407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 6 months therapy with 1,25 (OH)2D3 on bone disease of dialysis patients.
    Malluche HH; Goldstein DA; Massry SG
    Contrib Nephrol; 1980; 18():98-104. PubMed ID: 7353383
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of uremic osteopathy. Effects of vitamin D metabolites and vitamin D analogs in chronic uremia and experimental renal insufficiency].
    von Herrath D; Kraft D; Schaefer K; Krempien B
    MMW Munch Med Wochenschr; 1974 Sep; 116(37):1573-8. PubMed ID: 4374654
    [No Abstract]   [Full Text] [Related]  

  • 15. Adult-onset vitamin D-resistant osteomalacia with the unresponsiveness to parathyroid hormone.
    Fujita T; Nomura M; Okajima S; Furuya H
    J Clin Endocrinol Metab; 1980 May; 50(5):927-31. PubMed ID: 6246136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to vitamin D and parathyroid hormone.
    Moses AM
    N Engl J Med; 1978 Aug; 299(8):423-4. PubMed ID: 209328
    [No Abstract]   [Full Text] [Related]  

  • 17. 1,25-dihydroxycholecalciferol in hypophosphataemic osteomalacia presenting in adults.
    Offermann G; Delling G; Haussler MR
    Acta Endocrinol (Copenh); 1978 Jun; 88(2):408-16. PubMed ID: 580838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effects of 1,25-dihydroxycholecalciferol on disordered calcium metabolism of renal failure.
    Brickman AS; Coburn JW; Norman AW; Massry SG
    Am J Med; 1974 Jul; 57(1):28-33. PubMed ID: 4600292
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with 1,25-dihydroxycholecalciferol therapy in undergoing hemodialysis patients with progressive vitamin D2-treated osteodystrophy.
    Prior JC; Cameron EC; Ballon HS; Lirenman DS; Moriarty MV; Price JD
    Am J Med; 1979 Oct; 67(4):583-9. PubMed ID: 386792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodialysis patients with a unique mineralizing defect unresponsive to 1,25-dihydroxycholecalciferol. Dialysis osteomalacic syndrome.
    Cameron EC; Prior JC; Ballon HS
    Contrib Nephrol; 1980; 18():162-71. PubMed ID: 6986229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.